Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2015

01-11-2015 | Original Article

Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study

Authors: Yoshitaka Hashimoto, Muhei Tanaka, Toshihiro Kimura, Noriyuki Kitagawa, Masahide Hamaguchi, Mai Asano, Masahiro Yamazaki, Yohei Oda, Hitoshi Toda, Naoto Nakamura, Michiaki Fukui

Published in: Endocrine | Issue 2/2015

Login to get access

Abstract

Previous cross-sectional studies revealed an association between hemoglobin concentration and a prevalence of metabolic syndrome (MetS). However, the association between hemoglobin concentration and incident MetS remains to be elucidated. Thus, the aim of this study was to investigate the association between hemoglobin concentration and incident MetS. We enrolled 2695 subjects (1454 men and 1241 women) and performed 8-year follow-up cohort study. MetS was diagnosed, according to the joint interim statement, when a subject had three or more of the following components: hypertension; hyperglycemia; hypertriglyceridemia; low high-density lipoprotein cholesterol; and abdominal obesity. Logistic regression analyses were performed to assess the impact of hemoglobin concentration on incident MetS by adjusting for age, body mass index, lifestyle factors, including smoking status, habit of alcohol and habit of exercise, systolic blood pressure, fasting plasma glucose, triglycerides, high-density lipoprotein cholesterol, creatinine, and uric acid. The highest (≥157 g/L) and third (151–156 g/L) hemoglobin concentration quartiles were associated with the increased risk of incident MetS compared to the lowest (<145 g/L) hemoglobin concentration quartile after adjusting for covariates in men (multivariate odds ratio (OR) 2.24, 95 % CI 1.34–3.85, P = 0.0021 and multivariate OR 2.03, 95 % CI 1.21–3.45, P = 0.0070). On the other hand, there was no association between hemoglobin concentration and incident MetS in women. Hemoglobin concentration was a novel risk marker for incident MetS in men.
Literature
1.
J.I. Cleeman, S.M. Grundy, D. Becker, L.T. Clark, Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001)CrossRef
2.
H. Sone, S. Tanaka, S. Iimuro, K. Oida, Y. Yamasaki, S. Oikawa, S. Ishibashi, S. Katayama, H. Ito, Y. Ohashi, Y. Akanuma, N. Yamada, Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes. Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS). J. Atheroscler. Thromb. 16, 380–387 (2009)CrossRefPubMed
3.
4.
N. Miyatake, Y. Kawasaki, H. Nishikawa, S. Takenami, T. Numata, Prevalence of metabolic syndrome in Okayama prefecture, Japan. Intern. Med. 45, 107–108 (2006)CrossRefPubMed
5.
V. Lohsoonthorn, W. Jiamjarasrungsi, M.A. Williams, Association of hematological parameters with clustered components of metabolic syndrome among professional and office workers in Bangkok, Thailand. Diabetes Metab. Syndr. 1, 143–149 (2007)PubMedCentralCrossRefPubMed
6.
K. Nebeck, B. Gelaye, S. Lemma, Y. Berhane, T. Bekele, A. Khali, Y. Haddis, M.A. Williams, Hematological parameters and metabolic syndrome: findings from an occupational cohort in Ethiopia. Diabetes Metab. Syndr. 6, 22–27 (2012)PubMedCentralCrossRefPubMed
7.
R. Kawamoto, Y. Tabara, K. Kohara, T. Miki, T. Kusunoki, M. Abe, T. Katoh, Hematological parameters are associated with metabolic syndrome in Japanese community-dwelling persons. Endocrine 43, 334–341 (2013)CrossRefPubMed
8.
Y.Y. Wang, S.Y. Lin, P.H. Liu, B.M. Cheung, W.A. Lai, Association between hematological parameters and metabolic syndrome components in a Chinese population. J. Diabetes Complications 18, 322–327 (2004)CrossRefPubMed
9.
F.S. Facchini, M. Carantoni, J. Jeppesen, G.M. Reaven, Hematocrit and hemoglobin are independently related to insulin resistance and compensatory hyperinsulinemia in healthy, non-obese men and women. Metabolism 47, 831–835 (1998)CrossRefPubMed
10.
K.M. Choi, J. Lee, Y.H. Kim, K.B. Kim, D.L. Kim, S.G. Kim, D.H. Shin, N.H. Kim, I.B. Park, D.S. Choi, S.H. Baik, Koreans-Southwest Seoul (SWS) Study, Relation between insulin resistance and hematological parameters in elderly Koreans-Southwest Seoul (SWS) Study. Diabetes Res. Clin. Pract. 60, 205–212 (2003)CrossRefPubMed
11.
Y. Li, L. Liu, B. Wang, J. Wang, D. Chen, Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 26, 332–338 (2014)CrossRefPubMed
12.
S.G. Wannamethee, I.J. Perry, A.G. Shaper, Hematocrit and risk of NIDDM. Diabetes 45, 576–579 (1996)CrossRefPubMed
13.
L.J. Tamariz, J.H. Young, J.S. Pankow, H.C. Yeh, M.I. Schmidt, B. Astor, F.L. Brancati, Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the atherosclerosis risk in communities (ARIC) study. Am. J. Epidemiol. 168, 1153–1160 (2008)PubMedCentralCrossRefPubMed
14.
N. Nakanishi, K. Suzuki, K. Tatara, Haematocrit and risk of development of Type 2 diabetes mellitus in middle-aged Japanese men. Diabetes Med. 21, 476–482 (2004)CrossRef
15.
M.K. Tulloch-Reid, R.L. Hanson, A. Saremi, H.C. Looker, D.E. Williams, J. Krakoff, W.C. Knowler, Hematocrit and the incidence of type 2 diabetes in the pima indians. Diabetes Care 27, 2245–2246 (2004)CrossRefPubMed
16.
Y. Jiang, J. Zeng, B. Chen, Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. J. Gastroenterol. Hepatol. 29, 1508–1514 (2014)CrossRefPubMed
17.
D.R. Gagnon, T.J. Zhang, F.N. Brand, W.B. Kannel, Hematocrit and the risk of cardiovascular disease—the Framingham study: a 34-year follow-up. Am. Heart J. 127, 674–682 (1994)CrossRefPubMed
18.
D.W. Brown, W.H. Giles, J.B. Croft, Hematocrit and the risk of coronary heart disease mortality. Am. Heart J. 142, 657–663 (2001)CrossRefPubMed
19.
T. Kunnas, T. Solakivi, K. Huuskonen, A. Kalela, J. Renko, S.T. Nikkari, Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up. Prev. Med. 49, 45–47 (2009)CrossRefPubMed
20.
S. Matsuo, E. Imai, M. Horio, Y. Yasuda, K. Tomita, K. Nitta, K. Yamagata, Y. Tomino, H. Yokoyama, A. Hishida, Collaborators developing the Japanese equation for estimated GFR, Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982–992 (2009)CrossRefPubMed
21.
K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. Loria, S.C. Smith Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International. Circulation 120, 1640–1645 (2009)CrossRefPubMed
22.
T. Ota, T. Takamura, N. Hirai, K. Kobayashi, Preobesity in World Health Organization classification involves the metabolic syndrome in Japanese. Diabetes Care 25, 1252–1253 (2002)CrossRefPubMed
23.
M. Hamaguchi, T. Kojima, N. Takeda, T. Nakagawa, H. Taniguchi, K. Fujii, T. Omatsu, T. Nakajima, H. Sarui, M. Shimazaki, T. Kato, J. Okuda, K. Ida, The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 143, 722–728 (2005)CrossRefPubMed
24.
T. Nakamura, Y. Tsubono, K. Kameda-Takemura, T. Funahashi, S. Yamashita, S. Hisamichi, T. Kita, T. Yamamura, Y. Matsuzawa, Group of the research for the association between host origin and atherosclerotic diseases under the preventive measure for work-related diseases of the Japanese Labor Ministry.: magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Jpn. Circ. J. 65, 11–17 (2001)CrossRefPubMed
25.
M.R. Carnethon, C.M. Loria, J.O. Hill, S. Sidney, P.J. Savage, K. Liu, Coronary artery risk development in young adults study: risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 27, 2707–2715 (2004)CrossRefPubMed
26.
J.P. Gonçalves, A. Oliveira, M. Severo, A.C. Santos, C. Lopes, Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine 41, 450–457 (2012)CrossRefPubMed
27.
A. Moan, G. Nordby, I. Os, K.I. Birkeland, S.E. Kjeldsen, Relationship between hemorrheologic factors and insulin sensitivity in healthy young men. Metabolism 43, 423–427 (1994)CrossRefPubMed
28.
G. de Simone, R.B. Devereux, S. Chien, M.H. Alderman, S.A. Atlas, J.H. Laragh, Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation 81, 107–117 (1990)CrossRefPubMed
29.
T.A. Schultz, S.B. Lewis, D.K. Westbie, J.D. Wallin, J.E. Gerich, Glucose delivery: a modulator of glucose uptake in contracting skeletal muscle. Am. J. Physiol. 233, E514–E518 (1997)
30.
R. Kawamoto, Y. Tabara, K. Kohara, T. Miki, T. Kusunoki, S. Takayama, M. Abe, Hemoglobin is associated with serum high molecular weight adiponectin in Japanese community-dwelling persons. J. Atheroscler. Thromb. 18, 182–189 (2011)CrossRefPubMed
31.
A. Sonmez, M.I. Yilmaz, M. Saglam, S. Kilic, T. Eyileten, G. Uckaya, K. Caglar, Y. Oguz, A. Vural, M. Yenicesu, M. Kutlu, C. Kinalp, C. Zoccali, The relationship between hemoglobin levels and endothelial functions in diabetes mellitus. Clin. J. Am. Soc. Nephrol. 5, 45–50 (2010)PubMedCentralCrossRefPubMed
32.
W.A. Hsueh, M.J. Quiñones, Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol. 92, 10J–17J (2003)CrossRefPubMed
33.
T. Wang, Y. Bi, M. Xu, Y. Huang, Y. Xu, X. Li, W. Wang, G. Ning, Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. Endocrine 40, 109–116 (2011)CrossRefPubMed
34.
Y. Xu, M. Xu, Y. Huang, T. Wang, M. Li, Y. Wu, A. Song, X. Li, Y. Bi, G. Ning, Elevated serum γ-glutamyltransferase predicts the development of impaired glucose metabolism in middle-aged and elderly Chinese. Endocrine 40, 265–272 (2011)CrossRefPubMed
35.
Y. Xu, Z. Zhao, X. Li, Y. Bi, M. Xu, G. Ning, Relationships between C-reactive protein, white blood cell count, and insulin resistance in a Chinese population. Endocrine 39, 175–181 (2011)CrossRefPubMed
36.
Y. Xu, Y.F. Bi, M. Xu, Y. Huang, W.Y. Lu, Y.F. Gu, G. Ning, X.Y. Li, Cross-sectional and longitudinal association of serum alanine aminotransaminase and γ-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J. Diabetes. 3, 38–47 (2011)CrossRefPubMed
37.
M.A. Martínez-García, M. Luque-Ramírez, J.L. San-Millán, H.F. Escobar-Morreale, Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. Diabetes Care 32, 1525–1530 (2009)PubMedCentralCrossRefPubMed
38.
A. Ozdemir, C. Sevinç, U. Selamet, B. Kamaci, S. Atalay, Age- and body mass index-dependent relationship between correction of iron deficiency anemia and insulin resistance in non-diabetic premenopausal women. Ann. Saudi. Med. 27, 356–361 (2007)CrossRefPubMed
39.
R. Kawamoto, Y. Tabara, K. Kohara, T. Miki, T. Kusunoki, S. Takayama, M. Abe, T. Katoh, N. Ohtsuka, Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women. Endocrine 44, 132–139 (2013)PubMedCentralCrossRefPubMed
40.
Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity, New criteria for ‘obesity disease’ in Japan. Circ. J. 66, 987–992 (2002)CrossRef
41.
Metadata
Title
Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study
Authors
Yoshitaka Hashimoto
Muhei Tanaka
Toshihiro Kimura
Noriyuki Kitagawa
Masahide Hamaguchi
Mai Asano
Masahiro Yamazaki
Yohei Oda
Hitoshi Toda
Naoto Nakamura
Michiaki Fukui
Publication date
01-11-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0587-9

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue

Clinical Management of Endocrine Diseases

Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia

Original Article

Inverse association between serum total bilirubin levels and diabetic peripheral neuropathy in patients with type 2 diabetes

Original Article

Optimal cutoffs for low skeletal muscle mass related to cardiovascular risk in adults: The Korea National Health and Nutrition Examination Survey 2009–2010

Research Letter

Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus

Viewpoint

Classification of lung neuroendocrine tumors: lights and shadows

Original Article

Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits